-
calcium (3R,5R)-7-[2-(4-fluorophenyl)-4-[(4-oxidophenyl)carbamoyl]-3-phenyl-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate
-
ChemBase ID:
170259
-
Molecular Formular:
C33H33CaFN2O6
-
Molecular Mass:
612.7013232
-
Monoisotopic Mass:
612.19485599
-
SMILES and InChIs
SMILES:
c1(c(n(c(c1C(=O)Nc1ccc(cc1)[O-])C(C)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)c1ccc(cc1)F)c1ccccc1.[Ca+2]
Canonical SMILES:
O[C@@H](C[C@H](CC(=O)[O-])O)CCn1c(C(C)C)c(c(c1c1ccc(cc1)F)c1ccccc1)C(=O)Nc1ccc(cc1)[O-].[Ca+2]
InChI:
InChI=1S/C33H35FN2O6.Ca/c1-20(2)31-30(33(42)35-24-12-14-25(37)15-13-24)29(21-6-4-3-5-7-21)32(22-8-10-23(34)11-9-22)36(31)17-16-26(38)18-27(39)19-28(40)41;/h3-15,20,26-27,37-39H,16-19H2,1-2H3,(H,35,42)(H,40,41);/q;+2/p-2/t26-,27-;/m1./s1
InChIKey:
PXVKCBJKCBMVNK-CNZCJKERSA-L
-
Cite this record
CBID:170259 http://www.chembase.cn/molecule-170259.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
calcium (3R,5R)-7-[2-(4-fluorophenyl)-4-[(4-oxidophenyl)carbamoyl]-3-phenyl-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate
|
|
|
|
|
IUPAC Traditional name
|
|
calcium (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-4-[(4-oxidophenyl)carbamoyl]-3-phenylpyrrol-1-yl]-3,5-dihydroxyheptanoate
|
|
|
|
|
Synonyms
|
|
(βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-1H-pyrrole-1-heptanoic Acid Calcium Salt
|
|
p-Hydroxyatorvastatin Calcium Salt
|
|
4-Hydroxy Atorvastatin Calcium Salt
|
|
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
|
Data Source
|
Data ID
|
Price
|
|
TRC
|
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
|
Acid pKa
|
4.3280535
|
H Acceptors
|
6
|
H Donor
|
3
|
LogD (pH = 5.5)
|
3.8852012
|
LogD (pH = 7.4)
|
2.1372104
|
Log P
|
5.0835814
|
Molar Refractivity
|
181.5667 cm3
|
Polarizability
|
62.413193 Å3
|
Polar Surface Area
|
137.68 Å2
|
Rotatable Bonds
|
12
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
TRC
Toronto Research Chemicals -
H828961
|
|
4-Hydroxyatorvastatin is a hydroxylated metabolite of Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor. Atorvastatin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in pati |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Smith, S. et al.: Am. J. Cardiol., 80, 10H (1997)
- • Jacobsen, W. et al.: Drug Metab. Dispos., 28, 1369 (1997)
- • Istvan, E. et al.: Science, 292, 1160 (1997)
- • Tabernero, L. et al.: J. Biol. Chem., 278, 19933 (1997)
- • Bratton, L. et al.: Bioorg. Med. Chem., 15
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent